JP2022537987A5 - - Google Patents
Info
- Publication number
- JP2022537987A5 JP2022537987A5 JP2021574936A JP2021574936A JP2022537987A5 JP 2022537987 A5 JP2022537987 A5 JP 2022537987A5 JP 2021574936 A JP2021574936 A JP 2021574936A JP 2021574936 A JP2021574936 A JP 2021574936A JP 2022537987 A5 JP2022537987 A5 JP 2022537987A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1909500.9A GB201909500D0 (en) | 2019-07-02 | 2019-07-02 | Antagonist |
| GB1909500.9 | 2019-07-02 | ||
| GBGB1910526.1A GB201910526D0 (en) | 2019-07-23 | 2019-07-23 | Antagonist |
| GB1910526.1 | 2019-07-23 | ||
| GB2000906.4 | 2020-01-22 | ||
| GBGB2000906.4A GB202000906D0 (en) | 2020-01-22 | 2020-01-22 | Antagonist |
| PCT/GB2020/051573 WO2021001646A2 (en) | 2019-07-02 | 2020-06-30 | Apolipoprotein b antagonist |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022537987A JP2022537987A (ja) | 2022-08-31 |
| JPWO2021001646A5 JPWO2021001646A5 (https=) | 2023-07-07 |
| JP2022537987A5 true JP2022537987A5 (https=) | 2023-07-07 |
| JP7463410B2 JP7463410B2 (ja) | 2024-04-08 |
Family
ID=71949646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021574936A Active JP7463410B2 (ja) | 2019-07-02 | 2020-06-30 | アポリポタンパク質ｂアンタゴニスト |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230027604A1 (https=) |
| EP (1) | EP3965781A2 (https=) |
| JP (1) | JP7463410B2 (https=) |
| CN (1) | CN114072503A (https=) |
| CA (1) | CA3143404C (https=) |
| GB (1) | GB2585278B (https=) |
| WO (1) | WO2021001646A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202020534D0 (en) * | 2020-12-23 | 2021-02-03 | Argonaute Rna Ltd | Conjugate |
| US20250304966A1 (en) * | 2020-12-23 | 2025-10-02 | Argonaute RNA Limited | Treatment of cardiovascular disease |
| WO2023041508A2 (en) * | 2021-09-14 | 2023-03-23 | Argonaute RNA Limited | Treatment of cardiovascular disease |
| GB2618915B (en) * | 2022-05-18 | 2024-08-14 | Argonaute Rna Ltd | Treatment of cardiovascular disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7528118B2 (en) * | 2004-09-24 | 2009-05-05 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of ApoB and uses thereof |
| US8067572B2 (en) * | 2005-05-25 | 2011-11-29 | The University Of York | Hybrid interfering RNA |
| EP2105145A1 (en) * | 2008-03-27 | 2009-09-30 | ETH Zürich | Method for muscle-specific delivery lipid-conjugated oligonucleotides |
| US8236943B2 (en) * | 2009-07-01 | 2012-08-07 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein B |
| US20150025122A1 (en) * | 2009-10-12 | 2015-01-22 | Larry J. Smith | Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro |
| US10264976B2 (en) * | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
| KR20230043114A (ko) * | 2020-06-24 | 2023-03-30 | 사프렘 테크놀로지스 비.브이. | Galnac과 사포닌의 접합체, 상기 접합체 및 galnac-올리고뉴클레오티드 접합체를 포함하는 치료적 조성물 |
| US20250304966A1 (en) * | 2020-12-23 | 2025-10-02 | Argonaute RNA Limited | Treatment of cardiovascular disease |
-
2020
- 2020-06-30 US US17/620,973 patent/US20230027604A1/en not_active Abandoned
- 2020-06-30 CN CN202080048130.6A patent/CN114072503A/zh active Pending
- 2020-06-30 JP JP2021574936A patent/JP7463410B2/ja active Active
- 2020-06-30 WO PCT/GB2020/051573 patent/WO2021001646A2/en not_active Ceased
- 2020-06-30 CA CA3143404A patent/CA3143404C/en active Active
- 2020-06-30 EP EP20751621.2A patent/EP3965781A2/en active Pending
- 2020-06-30 GB GB2010004.6A patent/GB2585278B/en not_active Expired - Fee Related